KDMN Kadmon Holdings Inc.

4.66
+0.11  (+2%)
Previous Close 4.55
Open 4.74
Price To Book 7.77
Market Cap 745,722,469
Shares 160,026,281
Volume 11,744,321
Short Ratio 14.64
Av. Daily Volume 2,234,851
Stock charts supplied by TradingView

NewsSee all news

  1. Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

    ORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, RespectivelyKadmon Participating in FDA's Real-Time Oncology Review Pilot ProgramConference Call Today at 8:30 a.m. Eastern TimeNEW YORK, NY /

  2. Global Nanopharmaceuticals Market Analysis to 2020-2026 Covering Covid-19 Impact on Global Market

    “global Nanopharmaceuticals market” A new market study, titled "Covid-19 Impact on Global Nanopharmaceuticals Market Size, Status and Forecast 2020-2026" has been featured on WiseGuyReports. The global

  3. Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business Update

    NEW YORK, NY / ACCESSWIRE / March 13, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company held its pre-New Drug Application (NDA) meeting as scheduled with the U.S. Food and Drug Administration

  4. Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31,

  5. Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD

    Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020 NEW YORK, NY /

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data noted statistically significant Overall Response Rates (ORRs) of 73% with 200 mg once daily. NDA filing 4Q 2020.
KD025 - ROCKstar (KD025-213)
Chronic graft-versus-host disease (cGVHD)
Phase 2 data released February 12, 2018. Open label - noted data were "positive".
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 trial initiation announced July 9, 2019. Delays due to COVID-19.
KD025
Systemic sclerosis (scleroderma)
Phase 1 trial planned.
KD045
Fibrosis (kidney/lung/liver)

Latest News

  1. Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

    ORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, RespectivelyKadmon Participating in FDA's Real-Time Oncology Review Pilot ProgramConference Call Today at 8:30 a.m. Eastern TimeNEW YORK, NY /

  2. Global Nanopharmaceuticals Market Analysis to 2020-2026 Covering Covid-19 Impact on Global Market

    “global Nanopharmaceuticals market” A new market study, titled "Covid-19 Impact on Global Nanopharmaceuticals Market Size, Status and Forecast 2020-2026" has been featured on WiseGuyReports. The global

  3. Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business Update

    NEW YORK, NY / ACCESSWIRE / March 13, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company held its pre-New Drug Application (NDA) meeting as scheduled with the U.S. Food and Drug Administration

  4. Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31,

  5. Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD

    Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020 NEW YORK, NY /

  6. Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings

    NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that expanded data from the interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 in chronic

  7. Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan

    NEW YORK, NY and TOKYO, JAPAN / ACCESSWIRE / December 26, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN), a New York-based biopharmaceutical company, and Meiji Seika Pharma Co., Ltd, a Tokyo-based wholly owned subsidiary of

  8. Kadmon to Present Updated Data from Phase 2 Study of KD025 in cGVHD at the 61st ASH Annual Meeting & Exposition

    NEW YORK, NY / ACCESSWIRE / December 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that longer-term follow-up results from KD025-208, its ongoing Phase 2 study of KD025 in chronic graft-versus-host disease

  9. Kadmon Announces Closing of $101.6mm Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of common stock for gross

  10. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following investor

  11. Kadmon Announces Pricing of Public Offering of Common Stock

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon") today announced the pricing of an offering of 26,000,000 shares of its common stock at a public offering price of

  12. Kadmon Announces Proposed Public Offering of Common Stock

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) ("Kadmon") today announced its intention to offer and sell shares of its common stock in a public offering pursuant to its

  13. Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease

    KD025 Achieved ORRs of 64% with KD025 200 mg QD and 67% with KD025 200 mg BID Conference Call Today at 5:00 p.m. Eastern TimeNEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced

  14. Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and

  15. Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019."Following the

  16. Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plc

    NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company has entered into a transaction to divest approximately 1.4 million shares of MeiraGTx Holdings plc stock

  17. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / September 23, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following investor

  18. Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / September 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following investor conferences